Entre Ríos Starts Respiratory Syncytial Virus Vaccination
Respiratory Syncytial Virus (RSV) and Infant Health
Respiratory Syncytial Virus (RSV) is the leading cause of lower acute respiratory infections (LRTI) in children under one year of age. Centers for Disease Control and Prevention (CDC).
RSV commonly causes mild, cold-like symptoms, but can also led to more severe illness, such as bronchiolitis and pneumonia, requiring hospitalization. The CDC estimates that each year, RSV leads to approximately 60,000-160,000 hospitalizations and 60-160 deaths among young children in the United states. CDC – RSV Burden
RSV Prevention with Nirsevimab
Nirsevimab is a monoclonal antibody approved for the prevention of RSV in infants. It is administered as a single dose, ideally before or during the start of the RSV season, to significantly reduce the risk of severe RSV-related illness, including bronchiolitis, pneumonia, and hospitalization.
The U.S. food and Drug Governance (FDA) approved Beyfortus (nirsevimab-alip) in July 2023 for the prevention of RSV in infants up to 8 months old, and for some older infants through their first RSV season. FDA Approval of Nirsevimab
Clinical trials have demonstrated nirsevimab’s efficacy. For example, the MELODY trial showed approximately 80% efficacy against medically attended severe acute respiratory illness due to RSV in infants.Sanofi – MELODY Trial Results
RSV Seasonality and Timing of Nirsevimab Administration
RSV typically follows a seasonal pattern, with infections peaking during the fall and winter months. The timing of nirsevimab administration is crucial for optimal protection; it should be given prior to the start of the RSV season. CDC - RSV Transmission
The RSV season varies geographically. In most of the continental United States, the RSV season typically begins in the fall (October/November) and peaks in the winter (December/January). CDC – RSV Seasonal trends